Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.

By M. R. Janes, Jingchuan Zhang, Lian-Sheng Li, R. Hansen, U. Peters, Xin Guo, YuChing Chen, Anjali Babbar, Sarah J. Firdaus, L. Darjania and 24 more. Cell, 2018

993 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/b6bee5664566e510aea0d07ebefb281ff9dcb138

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. J. Christensen
2. Jill Hallin
3. Lars D. Engstrom
4. Lauren N. Hargis
5. Andrew Calinisan
6. Ruth Aranda
7. S. Ou
8. M. Johnson

Citations in the corpus

• The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients (2019, background): “In agreement with prior KRASG12C inhibitor studies (5), MRTX849 demonstrated improved potency in the 3-D assay format, as all but one KRASG12C-mutant cell line exhibited an IC50 value below 100 nmol/L.”